title: High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra.
abstract: The incidence of male urethral cancer is rare with age preponderance of 50 to 60 years. The standard management approach is surgery. Here, we present a novel treatment approach for male urethral cancer. Thirty-six year old male, case of primary clear cell adenocarcinoma of urethra who refused surgery, underwent cystoscopic assisted intraluminal HDR brachytherapy. Patient received a dose of 36 Gy in 9 fractions (4 Gy per fraction) followed by a boost of 24 Gy in 6 fractions. At 11 months post treatment, disease is well controlled with no post treatment toxicity so far. Intraluminal brachytherapy seems to be an effective novel treatment for male urethral cancer.
authors.affiliation: Department of Radiation Oncology.
authors.forename: Shirley
authors.initials: S
authors.lastname: Lewis
authors.affiliation: Department of Surgical Oncology.
authors.forename: Mahendra
authors.initials: M
authors.lastname: Pal
authors.affiliation: Department of Surgical Oncology.
authors.forename: Ganesh
authors.initials: G
authors.lastname: Bakshi
authors.affiliation: Department of Radiation Physics.
authors.forename: Yogesh G
authors.initials: YG
authors.lastname: Ghadi
authors.affiliation: Department of Pathology, Tata Memorial Centre, Parel, Mumbai, India.
authors.forename: Santosh
authors.initials: S
authors.lastname: Menon
authors.affiliation: Department of Radiation Oncology.
authors.forename: Vedang
authors.initials: V
authors.lastname: Murthy
authors.affiliation: Department of Radiation Oncology.
authors.forename: Umesh
authors.initials: U
authors.lastname: Mahantshetty
keywords: HDR brachytherapy; adenocarcinoma; intraluminal brachytherapy; urethral cancer